LCB1

An RBD-neutralizing miniprotein.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

LCB1 is a miniprotein designed and verified to neutralize the SARS-CoV-2 spike protein receptor binding domain (RBD) in vitro (Cao et al., 2020).

Link	Tested on	Impact factor	Notes	Publication date
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors Spike protein Biophysical assay Protein factor In vitro In silico	in silico; in vitro biophysical assay; Vero E6 cells	41.85	Small protein designed end experimentally (in vitro) verified to strongly bind to and inhibit the SARS-CoV-2 spike protein RBD.	Sep/09/2020

Link	Publication date
Computational Design of Miniproteins as SARS-CoV-2 Therapeutic Inhibitors	Jan/13/2022
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease	Jun/24/2021